Catalog No.
Product Name
Application
Product Information
Citations
-
NLRP3 Inhibitor
NT-0249 is a selective inhibitor of the NLRP3 inflammasome, targeting key inflammatory pathways. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research into diseases associated with inflammasome dysregulation. NT-0249 can be utilized in studies exploring the roles of NLRP3 in conditions such as autoimmune disorders and metabolic syndromes. -
NLRP3 Inflammasome Inhibitor
NLRP3-IN-NBC6 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 of 574 nM and functioning independently of calcium ions. It effectively inhibits Nigericin-induced inflammasome activation in THP-1 cells and reduces IL-1β release in response to Imiquimod from LPS-primed bone marrow-derived macrophages. This compound is valuable for studying the role of inflammasome activation in various inflammatory diseases and metabolic disorders. -
NLRP3/Pyroptosis Inhibitor
Antcin A is a potent inhibitor of the NLRP3 inflammasome, effectively disrupting its assembly and activation. This compound demonstrates significant biological activity by inhibiting pyroptosis in Kupffer cells, thereby offering liver protective properties. Antcin A is valuable for research focused on inflammation and can be particularly useful in studies related to non-alcoholic fatty liver disease. -
NLRP3 inflammasome Inhibitor
NBC19 is an inhibitor of the NLRP3 inflammasome, exhibiting an IC50 of 60 nM in differentiated THP1 cells. This compound effectively inhibits IL-1β release triggered by nigericin and ATP, with IC50 values of 80 nM and 850 nM, respectively. NBC19 serves as a valuable tool for investigating the role of the NLRP3 inflammasome in inflammatory processes and related research applications. -
NLRP3 Inhibitor
Selnoflast calcium is a selective and reversible small molecule inhibitor targeting the NLRP3 inflammasome. It effectively suppresses the release of IL-1β in response to NLRP3 activation, particularly in human monocyte-derived macrophages associated with Alzheimer's disease. This compound holds potential for advancing research in Alzheimer's as well as other systemic inflammatory diseases, including ulcerative colitis and chronic obstructive pulmonary disease. -
Anti-inflammatory Agent
NLRP3-IN-72 is a benzimidazole derivative that functions as an anti-inflammatory agent by specifically targeting the NLRP3 inflammasome. It demonstrates significant biological activity with an IC50 of 0.3 μM for inhibiting NLRP3-mediated IL-1β secretion, a PD50 of 0.4 μM for protecting against pyroptosis, and an EC50 of 0.6 μM for the induction of heme oxygenase-1 (HO-1). These properties make NLRP3-IN-72 a valuable tool for research into inflammatory processes and potential therapeutic interventions. -
NLRP3 Inhibitor
NLRP3-IN-44 is a selective inhibitor of the NLRP3 inflammasome, exhibiting potent activity with a Kd of 17.5 nM and approximately 62% oral bioavailability. This compound facilitates research into NLRP3-related pathologies by effectively modulating inflammasome activity. NLRP3-IN-44 is valuable for investigations into the roles of the NLRP3 inflammasome in inflammatory diseases. -
NLRP3 Inhibitor
NLRP3-IN-70 is an inhibitor of the NLRP3 inflammasome, specifically designed to bind to the NACHT domain of the NLRP3 protein. By blocking the interaction between NLRP3 and ASC, it disrupts ASC oligomerization and subsequent inflammasome assembly. This compound is valuable for research into conditions such as sepsis and nonalcoholic steatohepatitis, providing insights into the regulation of inflammatory responses. -
NLRP3 Inhibitor
NLRP3-IN-29 is a selective inhibitor of the NLR family pyrin domain-containing protein 3 (NLRP3). It demonstrates significant potential for blood-brain barrier permeability and efficacy in inhibiting inflammation both in vitro and in vivo. NLRP3-IN-29 is particularly valuable for research related to Alzheimer's disease and other neuroinflammatory conditions. -
NLRP3 Inhibitor
Yadanzigan is a potent NLRP3 inhibitor that exerts its anti-inflammatory effects by inhibiting the NF-κB signaling pathway and reducing Reactive Oxygen Species production. This compound has been shown to mitigate LPS-induced acute lung injury (ALI) in murine models, highlighting its potential for research in inflammation-related conditions. Its mechanism of action positions Yadanzigan as a valuable tool for studying NLRP3-related pathways and their roles in various pathological processes. -
NLRP3 Inhibitor
NLRP3-IN-9 is a potent inhibitor of the NLRP3 inflammasome, targeting its activation pathway. This compound effectively inhibits the release of interleukin-1 beta (IL-1β), thereby reducing inflammation and mechanical hyperalgesia. NLRP3-IN-9 has significant potential for research applications related to gout and other inflammatory disorders. -
NLRP3 Inhibitor
NLRP3-IN-43 is a potent inhibitor of NLRP3 inflammasome activation, specifically targeting the leucine-rich repeat (LRR) domain. By disrupting the interaction between NLRP3 and NEK7, this compound effectively inhibits the downstream signaling pathways associated with inflammatory responses. NLRP3-IN-43 is valuable for research applications focused on the modulation of inflammasome activity and its implications in various inflammatory diseases. -
NLRP3 Inhibitor
NLRP3-IN-41 is a selective inhibitor of the NLRP3 inflammasome, demonstrating significant anti-inflammatory and anti-neuroinflammatory effects without evident cytotoxicity. Its oral bioavailability and ability to penetrate the blood-brain barrier make it particularly valuable for studying the role of NLRP3 in neuroinflammatory conditions. NLRP3-IN-41 is suitable for research into inflammasome-related diseases, providing insights into the mechanism of NLRP3 activation and its contributions to pathological processes. -
NLRP3 Inhibitor
NLRP3-IN-37 is a potent inhibitor of the NLRP3 inflammasome, with an EC50 value of 5 nM. This compound is applicable in researching various NLRP3-related conditions, including gout, pseudogout, Cryopyrin-Associated Periodic Syndromes (CAPS), nonalcoholic steatohepatitis (NASH) fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's disease, Parkinson's disease, and traumatic brain injury. Its specificity for NLRP3 makes it a valuable tool in elucidating therapeutic approaches for these inflammatory disorders. -
NLRP3 Inflammasome Inhibitor
IIIM-1270 is a selective NLRP3 inflammasome inhibitor that effectively reduces the release of IL-1β in mouse macrophages (J774A.1 cells) with an IC50 of 3.5 μM. This compound significantly lowers the protein expression levels of mature IL-1β, making it a valuable tool for investigations into inflammatory pathways. IIIM-1270 is ideal for research applications focused on understanding the role of the NLRP3 inflammasome in various disease models related to inflammation. -
NLRP3 Inhibitor
NLRP3-IN-20 is a potent inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value of 25 nM for the secretion of IL-1β. This compound possesses strong pharmacokinetic properties, making it suitable for in vivo studies. NLRP3-IN-20 has shown significant efficacy in various research models, including non-alcoholic steatohepatitis, fatal septic shock, and colitis, thereby serving as a valuable tool for investigating inflammation-related disorders. -
NLRP3 Inflammasome Inhibitor
Fc 11a-2 is a benzimidazole compound that functions as a potent inhibitor of the NLRP3 inflammasome. It effectively reduces the activation of caspase-1, leading to decreased secretion of pro-inflammatory cytokines IL-1b and IL-18. This compound has demonstrated protective effects in model systems, including the prevention of Dextran sulfate sodium-induced murine experimental colitis, making it valuable for research in inflammation and related diseases. -
NLRP3 Inhibitor
MS-II-124 is a potent and selective inhibitor of the NLRP3 inflammasome, demonstrating an IC50 of 0.12 μM. This compound exhibits significant anti-inflammatory and immunomodulatory activities, making it a valuable tool for research applications related to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Its targeted inhibition of NLRP3 positions MS-II-124 as a promising candidate for elucidating the roles of inflammasomes in various inflammatory diseases. -
NLRP3 Inhibitor
NLRP3-IN-67 is a potent inhibitor of the NLRP3 inflammasome, which plays a critical role in mediating inflammatory responses. This compound effectively attenuates NLRP3 activation, thereby reducing the production of pro-inflammatory cytokines. NLRP3-IN-67 is valuable for research applications focused on inflammation-related diseases, such as autoimmune disorders and chronic inflammatory conditions. -
NLRP3 Inhibitor
NLRP3-IN-63 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an EC50 of 13 nM for NLRP3 activation inhibition. This compound provides a valuable tool for studying inflammatory responses and may aid in the research of diseases associated with NLRP3 dysregulation, such as autoinflammatory disorders and metabolic syndrome. Research applications include investigations into the mechanistic pathways of inflammation and the development of therapeutic strategies targeting NLRP3-related conditions. -
NLRP3 Inhibitor
NIC-12 is a selective NLRP3 inhibitor that effectively reduces circulating IL-1ß levels in models of LPS-induced endotoxemia in mice. This compound has been shown to inhibit NLRP3 inflammasome activation in mouse macrophages, making it a valuable tool for research into inflammatory responses and related diseases. Its application extends to studies focused on immunology and therapeutic interventions targeting NLRP3-related pathways. -
NLRP3 Inflammasome Inhibitor
IIIM-1266 is a potent NLRP3 inflammasome inhibitor that effectively inhibits the release of IL-1β in mouse macrophages (J774A.1 cells) with an IC50 of 2.3 μM. This compound significantly reduces the protein expression levels of mature IL-1β, making it a valuable tool for studying inflammation and its associated pathways in research settings. IIIM-1266 provides insights into the role of the NLRP3 inflammasome in inflammatory responses and potential therapeutic interventions. -
NLRP3 Inhibitor
NLRP3-IN-16 is a selective inhibitor of the NLRP3 inflammasome, demonstrating potent activity with an IC50 value of 0.065 μM for the inhibition of interleukin-1 beta (IL-1β) release. This compound provides valuable insights into the mechanisms of inflammation and is useful for research applications focused on inflammatory diseases and cellular stress responses. -
NLRP3 Inhibitor
NLRP3-IN-66 is a selective inhibitor of the NLRP3 inflammasome, which plays a crucial role in the activation of inflammatory responses. This compound demonstrates significant biological activity by reducing the production of pro-inflammatory cytokines, making it a valuable tool for research in inflammatory diseases. NLRP3-IN-66 is essential for studies targeting the modulation of the NLRP3 pathway in both in vitro and in vivo models. -
NLRP3 Modulator
NLRP3 Modulator 1 is a selective modulator targeting the NLRP3 inflammasome. This compound functions as an agonist or partial agonist, effectively enhancing NLRP3 activity. It is valuable for research into conditions, diseases, or disorders where reduced NLRP3 activity plays a role in disease pathology, facilitating studies on inflammation and immune responses. -
NLRP3 Inhibitor
NLRP3-IN-61 is a potent inhibitor of NLRP3, targeting the NLRP3 inflammasome pathway. This compound effectively inhibits pyroptosis in THP-1 cells with an IC50 value of 12.6 nM and reduces IL-1β release with an IC50 of 25.3 nM. NLRP3-IN-61 is suitable for research applications investigating inflammatory responses and therapeutic interventions in diseases associated with the NLRP3 inflammasome. -
NLRP3/URAT1 Inhibitor
NLRP3/URAT1-IN-1 is an orally active dual inhibitor targeting NLRP3 and URAT1, with an IC50 of 3.81 μM. This compound effectively inhibits IL-1β release in LPS- and ATP-stimulated mouse bone marrow-derived macrophages, demonstrating an IC50 of 2.61 μM. In vivo studies reveal that NLRP3/URAT1-IN-1 significantly reduces serum uric acid levels and mitigates liver and kidney damage in models of acute hyperuricemia. This reagent is essential for investigating the pathophysiology of gout and hyperuricemia. -
NOD-like Receptor (NLR) Inhibitor
Apilimod hydrochloride is an inhibitor of the PIKFYVE kinase, targeting the NOD-like receptor (NLR) pathway. This compound facilitates the activation of NLRP3 inflammatory vesicles and promotes the secretion of IL-1β. Its ability to inhibit host cell proteases may prevent viral invasion; however, it may also obstruct antiviral immune responses, which could lead to increased immunosuppression in conditions such as COVID-19. Research applications include studies on inflammation, immune response regulation, and viral pathogenesis. -
NLRP3 Degrader
MC-ND-18 is an ATTEC degrader targeting NLRP3, functioning primarily through autophagic pathways. With a DC50 value of 125.5 nM in THP-1 cells, this compound facilitates the selective degradation of NLRP3. Composed of a ligand specific to NLRP3, a linker, and an LC3 ligand, MC-ND-18 is valuable for research investigating inflammation and diseases associated with NLRP3 activation. -
NLRP3 Inflammasome Inhibitor
YM-I-26 is a selective inhibitor of the NLRP3 inflammasome, effectively modulating inflammatory responses. It enhances the phagocytosis of β-amyloid protein by mouse microglial BV2 cells while concurrently inhibiting the secretion of pro-inflammatory cytokines IL-1β and IL-10. This compound is useful for investigating the role of the NLRP3 inflammasome in various inflammatory conditions and its potential as a therapeutic target in immune modulation. -
NLRP3 Inhibitor
Isoandrographolide is a selective inhibitor of the NLRP3 inflammasome, known for its potential to modulate inflammatory responses. This compound exhibits significant hepatoprotective effects and promotes cell differentiation. Research applications include studying the role of NLRP3 in inflammatory diseases and exploring therapeutic strategies for conditions such as silicosis. -
Sodium Channel Inhibitor
Articaine is a selective inhibitor of voltage-gated sodium channels, including rNav1.4, hNav1.7, and rNav1.8, demonstrating an IC50 of 15.8 μM for open-state Na+ channels. It effectively blocks Na+ influx, leading to local anesthetic effects and interruption of nerve impulse conduction. Additionally, Articaine exhibits anti-inflammatory properties by inhibiting NF-κB activation and the NLRP3 inflammasome pathway. This compound is valuable for research in dental anesthesia and inflammatory-related conditions, such as acute kidney injury. -
NLRP3 Inhibitor
NLRP3-IN-27 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value of 0.55 μM. This compound is instrumental in investigating the role of NLRP3 in inflammatory processes and immune response modulation. It is a valuable tool for researchers studying the molecular mechanisms of inflammation and potential therapeutic strategies for associated diseases. -
NLRP3 Inflammasome Inhibitor
NLRP3-IN-86 is a selective inhibitor of the NLRP3 inflammasome. This compound demonstrates significant potency in reducing lipopolysaccharide (LPS) and Nigericin-induced lactate dehydrogenase release, with IC50 values of 2.69 μM in THP-1 cells and 1.75 μM in J774A.1 cells. Additionally, NLRP3-IN-86 effectively inhibits gasdermin D cleavage and interleukin-1 beta (IL-1β) secretion, thereby mitigating pyroptosis. This reagent is ideally suited for investigations into inflammatory processes and the underlying mechanisms of pyroptotic cell death. -
NLRP3 Inhibitor
NLRP3-IN-8 is a potent inhibitor of the NLRP3 inflammasome, acting through direct binding with an IC50 of 1.23 μM against IL-1β. This compound demonstrates notable metabolic stability, with a half-life of 138.63 minutes in liver microsomes, and exhibits minimal toxicity, as indicated by an IC50 greater than 100 μM against L02 cells. NLRP3-IN-8 is valuable for research into inflammatory disorders and potential therapeutic interventions targeting the NLRP3 pathway. -
NLRP3 Inhibitor
NLRP3-IN-31 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value in the range of 0.3-0.5 μM. This compound effectively modulates the activation of NLRP3, making it a valuable tool for studying inflammatory pathways. NLRP3-IN-31 can be utilized in research focused on autoinflammatory diseases, metabolic disorders, and neuroinflammation, aiding in the understanding of inflammasome-mediated processes. -
NLRP3 Inhibitor
NLRP3-IN-15 is a selective inhibitor of the NLRP3 inflammasome, targeting the pathway responsible for the activation of pro-inflammatory cytokines. With an IC50 of 0.114 μM, NLRP3-IN-15 effectively inhibits the release of IL-1β, a key mediator in inflammatory responses. This compound is suitable for investigating the role of NLRP3 in various inflammatory disorders and related research applications. -
NEK7 Degrader
NEK7 degrader-2 (Compound 25) is a targeted NEK7 degrader that facilitates dose-dependent degradation of NEK7 specifically in human PBMC-derived macrophages. This compound effectively reduces the release of pro-inflammatory cytokine IL-1β triggered by NLRP3 inflammasome activation. NEK7 degrader-2 serves as a valuable tool for investigating the mechanisms underlying inflammatory diseases. -
NLRP3 Inhibitor
NLRP3-IN-69 is a selective inhibitor of the NLRP3 inflammasome, targeting the activation of NF-κB p65. This compound effectively reduces LPS-induced overexpression of pro-inflammatory cytokines including IL-1β, as well as iNOS and COX-2, while inhibiting nitric oxide generation with an IC50 of 5.66 μM. NLRP3-IN-69 serves as a valuable tool in research focused on inflammatory diseases and the modulation of the immune response. -
NLRP3 Inhibitor
NLRP3-IN-62 is a selective inhibitor of the NLRP3 inflammasome, demonstrated to effectively inhibit pyroptosis in THP-1 cells with an IC50 of 0.7 nM. Additionally, it suppresses the release of interleukin-1 beta (IL-1β) with an IC50 of 108.5 nM. This compound serves as a valuable tool for research in inflammation and immune responses, particularly in studies related to diseases involving pyroptotic cell death. -
NLRP3 Modulator
NLRP3 Modulator 7 is a specific inhibitor of the NLRP3 inflammasome, effectively regulating its activity. This compound demonstrates potent inhibitory effects on interleukin-1 beta (IL-1β) secretion, with an IC50 value of less than 500 nM. NLRP3 Modulator 7 is applicable in research focused on inflammatory diseases and disorders related to the NLRP3 pathway. -
NLRP3 Inflammasome Inhibitor
NLRP3-IN-77 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an IC50 value of 5.36 nM in suppressing the viability of THP-1 cells. This compound effectively reduces the secretion of pro-inflammatory cytokines, specifically interleukin-1β (IL-1β) and interleukin-18 (IL-18). NLRP3-IN-77 is a valuable tool for investigating diseases associated with aberrant NLRP3 inflammasome activation, including various cancers and inflammatory disorders. -
Anti-inflammatory Agent
Macarangin is an anti-inflammatory agent isolated from propolis. It exhibits significant DPPH radical-scavenging activity and demonstrates anti-inflammatory effects by inhibiting the activation of the NLRP3 inflammasome. This compound is valuable for research applications focused on inflammation pathways and oxidative stress. -
NLRP3 Inhibitor
NLRP3-IN-22 is a selective inhibitor of the NLRP3 inflammasome, demonstrating an inhibition rate of 67% at a concentration of 10 μM. This compound is useful for studying the role of NLRP3 in inflammatory processes and can be applied in various research areas, including immunology and disease models related to chronic inflammation. Its selective inhibition makes it a valuable tool for elucidating the mechanisms underlying NLRP3-mediated pathologies. -
NLRP3 Inhibitor
Selnoflast monopotassium is a selective and reversible small molecule inhibitor targeting the NLRP3 inflammasome. It effectively inhibits IL-1β release induced by NLRP3 activation in monocyte-derived macrophages from individuals with Alzheimer's disease. This compound shows significant promise for research applications related to Alzheimer's disease and other systemic inflammatory disorders, including ulcerative colitis and chronic obstructive pulmonary disease. -
COX-2/NLRP3 Inhibitor
COX-2/NLRP3-IN-1 is a selective inhibitor targeting both COX-2 and the NLRP3 inflammasome, with an IC50 of 1.53 μM for COX-2. This compound exhibits notable anti-inflammatory properties by disrupting the NF-κB/NLRP3 signaling pathway, making it a valuable tool for research into inflammatory diseases. It is suitable for studying the roles of COX-2 and NLRP3 in various biological processes and therapeutic interventions. -
NLRP3 Inhibitor
NLRP3-IN-38 is a selective inhibitor of the NOD-like receptor protein 3 (NLRP3), known for its role in mediating inflammatory responses through inflammasome activation. With an EC50 value of 23 nM, it effectively reduces the activation of the NLRP3 inflammasome, making it a valuable tool for research into inflammatory diseases. This compound is suited for studies evaluating the modulation of NLRP3-related signaling pathways and the development of therapeutic strategies targeting NLRP3-mediated inflammation. -
NLRP3 Inhibitor
NLRP3-IN-82 is a potent inhibitor of the NLRP3 inflammasome, exhibiting an IC50 of less than 5 nM. This compound demonstrates significant biological activity in the modulation of inflammatory pathways and is applicable in research focused on neurological diseases such as Alzheimer's disease, inflammatory conditions like inflammatory bowel disease, and metabolic disorders including obesity. Its selective inhibition of NLRP3 makes it a valuable tool for studying the underlying mechanisms of these pathologies. -
NLRP3 Inhibitor
NLRP3-IN-14 is a selective inhibitor of the NLRP3 inflammasome, exhibiting a binding affinity (KD) of 5.87 μM. This compound effectively inhibits the release of interleukin-1 beta (IL-1β), with an IC50 value of 0.131 μM. NLRP3-IN-14 is valuable for research into inflammatory processes and the development of therapeutics targeting NLRP3-associated diseases. -
NLRP3 Inhibitor
NLRP3-IN-34 is a potent inhibitor of the NLRP3 inflammasome, targeting its activation and downstream signaling. It effectively inhibits reactive oxygen species (ROS) production and interleukin-1 beta (IL-1β) release, exhibiting an IC50 of 0.48 μM in J774A.1 cells. Additionally, NLRP3-IN-34 has demonstrated the capability to inhibit pyroptosis and exhibits anti-inflammatory effects, particularly in models of dextran sulfate sodium (DSS)-induced peritonitis. This compound is valuable for research focused on inflammation and related disease mechanisms.
